Key Takeaways Amvuttra drove $801.9 million in H1 2025 sales, up 89% year over year.U.S. and EU nods expanded Amvuttra's use to ATTR-CM, boosting uptake.Competition from Pfizer's Vyndaqel and BridgeBio's Attruby poses challenges.Alnylam Pharmaceuticals (ALNY) is a commercial-stage company that currently markets four drugs. The company first received regulatory approval in 2018 for Onpattro to treat adult patients with hereditary transthyretin-mediated (hATTR) amyloidosis. Subsequently, ALNY received approva ...